Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Yuki S, et al. Among authors: shimokawa m. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25. Cancer Chemother Pharmacol. 2020. PMID: 31768696 Clinical Trial.
Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Oki E, Emi Y, Kusumoto T, Sakaguchi Y, Yamamoto M, Sadanaga N, Shimokawa M, Yamanaka T, Saeki H, Morita M, Takahashi I, Hirabayashi N, Sakai K, Orita H, Aishima S, Kakeji Y, Yamaguchi K, Yoshida K, Baba H, Maehara Y. Oki E, et al. Among authors: shimokawa m. Ann Surg Oncol. 2014 Jul;21(7):2340-6. doi: 10.1245/s10434-014-3594-9. Epub 2014 Mar 7. Ann Surg Oncol. 2014. PMID: 24604583 Clinical Trial.
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan. Tamura K, et al. Among authors: shimokawa m. Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15. Int J Clin Oncol. 2015. PMID: 25681876
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Ogata Y, et al. Among authors: shimokawa m. Int J Clin Oncol. 2016 Apr;21(2):335-343. doi: 10.1007/s10147-015-0895-3. Epub 2015 Sep 4. Int J Clin Oncol. 2016. PMID: 26338269 Free PMC article. Clinical Trial.
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. Miyamoto Y, et al. Among authors: shimokawa m. Int J Clin Oncol. 2016 Aug;21(4):705-712. doi: 10.1007/s10147-015-0943-z. Epub 2016 Jan 8. Int J Clin Oncol. 2016. PMID: 26746689 Clinical Trial.
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T, Mishima H, Sawaki A, Shimokawa M, Inukai M, Shinozaki K, Tanioka H, Nasu J, Nishina T, Hazama S, Okajima M, Yamaguchi Y. Nagasaka T, et al. Among authors: shimokawa m. BMJ Open. 2016 Jun 2;6(6):e011454. doi: 10.1136/bmjopen-2016-011454. BMJ Open. 2016. PMID: 27256093 Free PMC article. Clinical Trial.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takahashi T, et al. Among authors: shimokawa m. Cancer Chemother Pharmacol. 2016 Sep;78(3):585-93. doi: 10.1007/s00280-016-3109-4. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468920 Clinical Trial.
463 results